14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Jan 16, 2026
TEF vs MNMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Jan 16, 2026, Telefonica, S.A. (TEF) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TEF carries a Unified Composite Score of 56.8/100 (HOLD) at $3.81 (15.6x Forward P/E, 13.0% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. TEF 56.8/100 HOLD), TEF captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (13.0% vs. 0.0% operating margin) and revenue trajectory (-6.6% vs. +0.0% YoY).
Technical & Structure Timing Caution: TEF is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.9); meanwhile MNMD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TEF vs MNMD. Trailing 12-month operating profitability (TEF 13.0% vs MNMD 0.0%) and valuation multiples (TEF 15.6x vs MNMD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ TEF vs MNMD Key Questions & Quantitative Answers
As of Jan 16, 2026, Telefonica, S.A. (TEF) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TEF carries a Unified Composite Score of 56.8/100 (HOLD) at $3.81 (15.6x Forward P/E, 13.0% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. TEF 56.8/100 HOLD), TEF captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (13.0% vs. 0.0% operating margin) and revenue trajectory (-6.6% vs. +0.0% YoY). Technical & Structure Timing Caution: TEF is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.9); meanwhile MNMD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MNMD leads the Growth & Scale pillar: TEF posts -6.6% YoY revenue growth and N/A YoY earnings growth on $41.6B TTM revenue (54.5% gross margin, 13.0% operating margin), compared with MNMD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TEF generates $41.6B in USD-normalized revenue versus N/A for MNMD. In operating R&D and SG&A reinvestment, TEF deploys 41.5% of Rev ($17.3B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNMD.
TEF screens cheaper on headline valuation multiples. TEF trades at 15.6x Forward P/E, 12.6x Trailing P/E, 0.34x PEG, and 0.5x EV/Revenue (22.8% EBITDA margin), whereas MNMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TEF (-2.3% ROE) versus MNMD (-85.6% ROE) capital efficiency.
In options market volatility and institutional positioning, TEF carries 40.4% implied volatility (47th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 25% Vol realized risk). By comparison, MNMD carries 70.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jan 16, 2026. For educational research only; not investment advice.